Clinical Trial: Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07681167) titled 'Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial' on June 11.

Brief Summary: Dysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated neovascularization.

This study prospectively evaluates the efficacy and safety of faricimab compared to sham in CSCR with and without secondary neovascularization, using standardized anatomical and functional endpoints. The results of this tr...